August 7, 2022
8:50 pm - 9:20 pm
Nigel Swain (Sosei Heptares, United Kingdom)
"Discovery of HTL0039732: A Potent and Selective EP4 Receptor Antagonist for Cancer Immunotherapy"
Dr Alexander A. Azizi（LinkedIn）
NIHR Academic Clinical Fellow in Medical Oncology
Experimental Medicine Physician & Clinical Development Scientist
Sosei Heptares
2020年11月 – 現在1年 7ヶ月
A world-leader in G-protein coupled receptor (GPCR) medicine design and development.
Deputy clinical lead for HTL0039732 project.
Deputy clinical lead for HTL0039732 first-in-human clinical trial design.
Translational lead for cancer bioinformatics.
Translational co-lead for immunogenomic companion diagnostic development.
£10-15 million secured for Phase I/IIa trial as part of 7 person core team.
自社開発品目であるEP4 antagonist(HTL0039732)の開発状況として、Nigel Swain博士とAlexander A. Azizi博士の情報がありますね。
これはSoseiHeptaresがCancer Immunotherapy分野でNIHと関係してくるということなのでしょうか？
であるならばかなりの朗報で、自社での権利を確保しながら治験実施コストの削減にもなってくるという、以前の野村氏のブログ内容とも整合性が出てきますね。
Medicinal Chemistry
Gordon Research Conference
August 7, 2022
8:50 pm - 9:20 pm
Nigel Swain (Sosei Heptares, United Kingdom)
"Discovery of HTL0039732: A Potent and Selective EP4 Receptor Antagonist for Cancer Immunotherapy"
Dr Alexander A. Azizi（LinkedIn）
NIHR Academic Clinical Fellow in Medical Oncology
Experimental Medicine Physician & Clinical Development Scientist
Sosei Heptares
2020年11月 – 現在1年 7ヶ月
A world-leader in G-protein coupled receptor (GPCR) medicine design and development.
Deputy clinical lead for HTL0039732 project.
Deputy clinical lead for HTL0039732 first-in-human clinical trial design.
Translational lead for cancer bioinformatics.
Translational co-lead for immunogenomic companion diagnostic development.
£10-15 million secured for Phase I/IIa trial as part of 7 person core team.